Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Magenta Therapeutics, Inc. (MGTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
10/04/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
10/03/2023 4 Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/
Txns: Bought 24,670 shares @ $13.63, valued at $336.3k
09/28/2023 4 Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/
Txns: Bought 30,000 shares @ $13.15, valued at $394.5k
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/01/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/31/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
07/17/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
05/19/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/15/2023 SC 13G CITADEL ADVISORS LLC reports a 6.7% stake in Magenta Therapeutics, Inc.
05/15/2023 S-4 Form S-4 - Registration of securities, business combinations:
05/03/2023 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
05/03/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/03/2023 8-K Quarterly results
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/06/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/31/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan"
03/31/2023 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in MAGENTA THERAPEUTICS, INC.
02/14/2023 SC 13G/A Aquilo Capital Management, LLC reports a 0% stake in Magenta Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A GILDER GAGNON HOWE & CO LLC reports a 0.7% stake in Magenta Therapeutics, Inc.
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 4 Third Rock Ventures IV, L.P. (10% Owner) has filed a Form 4 on Magenta Therapeutics, Inc.
Txns: Sold 2,200,000 shares @ $0.83, valued at $1.8M
Sold 1,500,000 shares @ $0.82, valued at $1.2M
02/07/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
02/02/2023 8-K Quarterly results
01/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety"
12/20/2022 8-K Quarterly results
12/13/2022 8-K Quarterly results
12/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy